Axa
SRNE

Axa’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Axa’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-774,200
Closed -$686K – 1211
2022
Q4 		$686K Buy
774,200
+346,900
+81% +$460K ﹤0.01% 943
2022
Q3 		$671K Hold
427,300
– – ﹤0.01% 921
2022
Q2 		$859K Buy
+427,300
New +$739K ﹤0.01% 900
2022
Q1 		– Sell
-29,800
Closed -$139K – 1261
2021
Q4 		$139K Hold
29,800
– – ﹤0.01% 1131
2021
Q3 		$227K Buy
+29,800
New +$253K ﹤0.01% 1174
2020
Q2 		– Sell
-68,600
Closed -$126K – 1308
2020
Q1 		$126K Hold
68,600
– – ﹤0.01% 1133
2019
Q4 		$232K Sell
68,600
-2,400
-3% -$5.72K ﹤0.01% 1113
2019
Q3 		$152K Hold
71,000
– – ﹤0.01% 1262
2019
Q2 		$190K Sell
71,000
-58,300
-45% -$210K ﹤0.01% 1236
2019
Q1 		$614K Sell
129,300
-160,800
-55% -$422K ﹤0.01% 1072
2018
Q4 		$696K Hold
290,100
– – ﹤0.01% 1029
2018
Q3 		$1.28M Buy
290,100
+219,500
+311% +$1.22M ﹤0.01% 981
2018
Q2 		$508K Buy
+70,600
New +$480K ﹤0.01% 1132

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Axa's SRNE Position: Q1 2023 in Review

Axa sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 774,200 shares — an estimated $686K sold.

Axa first reported a position in SRNE in Q2 2018 and held it in 13 quarters. The position peaked at $1.28M in Q3 2018. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Axa reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Axa sold 774,200 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $686K.
  • Axa first reported a position in Sorrento Therapeutics, Inc. in Q2 2018 and held it in 13 quarters.
  • Axa's Sorrento Therapeutics, Inc. position peaked at $1.28M in Q3 2018.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Axa's 13F filing for Q1 2023, filed 15 May 2023.